5Y Capital
5Y Capital is a private equity and venture capital firm based in Shanghai, China, focused on seed, start-up, early venture, and growth capital investments. Founded in 2008 and previously known as Morningside Venture Capital, the firm manages approximately USD 5 billion in dual-currency funds, supported by global investors such as sovereign wealth funds, family offices, and endowments. 5Y Capital primarily invests in various sectors, including healthcare, technology, fintech, media, software, life sciences, and education, with a special emphasis on medical treatment, biotechnology, and digital health. The firm seeks opportunities in China and other emerging markets across Asia and the Pacific, aiming to support entrepreneurs in building innovative companies. 5Y Capital typically makes initial investments exceeding USD 500,000 per portfolio company and operates as a subsidiary of Morningside Group, which has been active in venture capital investments since 1992.
Amylyx Pharmaceuticals, Inc. develops novel therapeutic for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases. It offers AMX0035, an investigational therapy and a fixed-dose co-formulation of two active compounds, such as sodium phenylbutyrate and Taurursodiol optimized to treat both the energy crisis in the mitochondria and the toxic, unfolded proteins in the endoplasmic reticulum, disrupting the neurological chain of events that leads to patient suffering. The company’s pipeline includes amyotrophic lateral sclerosis, Wolfram syndrome, and Alzheimer’s diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.
Amylyx Pharmaceuticals, Inc. develops novel therapeutic for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases. It offers AMX0035, an investigational therapy and a fixed-dose co-formulation of two active compounds, such as sodium phenylbutyrate and Taurursodiol optimized to treat both the energy crisis in the mitochondria and the toxic, unfolded proteins in the endoplasmic reticulum, disrupting the neurological chain of events that leads to patient suffering. The company’s pipeline includes amyotrophic lateral sclerosis, Wolfram syndrome, and Alzheimer’s diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.
Boohee provides you with tailor-made weight loss programs, simple and effective weight loss tools, supplemented by slimming courses, weight loss forums and food calorie enquiries, so that you are thin and healthy, thin and beautiful!
The Nue Co. Ltd. specializes in the production of science-backed nutritional supplements derived from organic ingredients. Founded in 2016 and based in London, the company emphasizes simplicity and creativity, inspired by Danish principles. Its product range includes vitamins, milk protein, plant protein, magnesium, prebiotics, and probiotics, all formulated without toxic preservatives, additives, or fillers. The ingredients are responsibly sourced and clinically proven to address various health concerns, including fatigue, skin issues, inflammation, and digestive problems. The Nue Co. operates on a subscription model through its online platform, ensuring that consumers have easy access to high-quality supplements. Committed to sustainability, the company limits plastic packaging and aims to reduce its carbon footprint, while maintaining transparency and high standards in ingredient sourcing.
Elysium Health, Inc. develops and produces health supplements focused on cellular health, long-term brain health, and biological age testing. Founded in 2014 and based in New York, the company sells its products online, aiming to enhance health and longevity through scientifically backed solutions. Elysium collaborates with scientists, clinicians, and health professionals globally to identify and formulate natural compounds. Its flagship product features a proprietary combination of ingredients designed to support overall well-being at the cellular level, addressing contemporary health challenges with a foundation in scientific research.
Amylyx Pharmaceuticals, Inc. develops novel therapeutic for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases. It offers AMX0035, an investigational therapy and a fixed-dose co-formulation of two active compounds, such as sodium phenylbutyrate and Taurursodiol optimized to treat both the energy crisis in the mitochondria and the toxic, unfolded proteins in the endoplasmic reticulum, disrupting the neurological chain of events that leads to patient suffering. The company’s pipeline includes amyotrophic lateral sclerosis, Wolfram syndrome, and Alzheimer’s diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.